Latest News
Rapport Therapeutics, Inc.
- Form 4 Rapport Therapeutics Inc: John Maraganore (Director) For: 22 October
- Rapport Therapeutics director Wendy Young buys $99,991 in shares By Investing.com
- Rapport Therapeutics director John Maraganore acquires $248,891 in stock By Investing.com
- Rapport Therapeutics director Paul M. buys $974k in shares By Investing.com
- Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Rises
- Rapport Therapeutics Stock Jumps. Analysts See a Potential Blockbuster Drug.
- Truist reiterates Rapport Therapeutics stock rating on trial data By Investing.com
- TD Cowen reiterates Buy on Rapport Therapeutics stock after trial By Investing.com
- Why Is Rapport Therapeutics Stock Trading Higher Today?
- Rapport Therapeutics reports positive Phase 2 RAP-219 results; meets YMRS primary endpoint, Phase 3 planned
- Rapport Therapeutics Announces Positive Topline Results From Its Phase 2 Trial Of Rap-219 For The Treatment Of Bipolar Mania
- Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
Headlines from the last 30 days, linking to the original publishers. See all market news →